9th International Congress on Autoimmunity (Nice)
On March 26. – 30. 2014 over 2000 scientists from around the world met in Nice for the 9th International Congress on Autoimmunity.
Immunologists form basic research, industry and over 700 clinicians presented and discussed the latest developments in the research and treatment of auto-immune diseases.
MetrioPharm's president of the board and CSO Dr. Wolfgang Brysch presented new results on the efficacy and safety of MP1000 in disease models of rheumatoid arthritis.
In the context of all currently available arthritis treatments as well as the other new therapies in development, which were discussed at this conference, it became clear that MP1000 is very unique in the field of immune regulating drugs.
All other drugs that were presented at the conference act more or less as immune-suppressors and thus inevitably lead to an increased risk of severe infections.
MP1000 is the first and currently only drug which overcomes this inherent risk of all classical immune-suppressive drugs by having both anti-inflammatory and anti-infective effects at the same time.
The results presented by MetrioPharm which clearly demonstrate this twofold effect created a highly positive response from the scientific audience and keen interest in this new drug principle.
